{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040176","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.026859+00:00","generated_at":"2026-06-04T05:56:38.138925+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS partner GenFleet doses first patient in Phase Ib/II combo trial of GFH009 + BRUKINSA for DLBCL","bullets":["GenFleet entered clinical trial collaboration with BeiGene for GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib).","First patient dosed in open-label, single-arm, multi-center Phase Ib/II trial for relapsed/refractory DLBCL in China.","Trial evaluates safety and efficacy of the combination therapy; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040176","json":"https://secwatch.observer/filing/0001104659-24-040176.json","markdown":"https://secwatch.observer/filing/0001104659-24-040176.md","text":"https://secwatch.observer/filing/0001104659-24-040176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924040176/0001104659-24-040176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924040176/tm2410063d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:56:38.138925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}